CONTRAINDICATIONS (This product is contraindicated in the following patients.)

(1) Patients with glaucoma
   [Administration of this product may increase intraocular pressure.]
(2) Patients with dysuria due to prostatic hyperplasia
   [Symptoms may be exacerbated.]
(3) Patients with serious cardiac disease
   [Symptoms may be exacerbated.]
(4) Patients with paralytic ileus
   [Symptoms may be exacerbated.]
(5) Patients with a history of hypersensitivity to any of the ingredients of this product.

DESCRIPTION

Product description

<table>
<thead>
<tr>
<th>Ingredient/content per tablet</th>
<th>Piperidolate hydrochloride 50 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inactive ingredients</td>
<td>Lactose hydrate, crystalline cellulose, corn starch, povidone, magnesium stearate, hypromellose, macrogol 6000, titanium oxide, silicone resin</td>
</tr>
<tr>
<td>Dosage form</td>
<td>Film-coated</td>
</tr>
<tr>
<td>Color</td>
<td>White</td>
</tr>
<tr>
<td>Appearance</td>
<td>8.2 mm in diameter 3.9 mm in thickness About 200 mg in weight</td>
</tr>
<tr>
<td>Identification code</td>
<td>KP-123</td>
</tr>
</tbody>
</table>

INDICATIONS

Convulsive pain in the following diseases:
Gastroduodenal ulcer, gastritis, enteritis, cholelithiasis, cholecystitis, and biliary dyskinesia.
Improvement in various symptoms in threatened abortion or premature delivery.

DOSAGE AND ADMINISTRATION

The usual adult dosage of this product for oral use is 150 to 200 mg (3 or 4 tablets) of Piperidolate hydrochloride daily in 3 or 4 divided doses. The dosage may be adjusted according to the patients’ ages and symptoms.

PRECAUTIONS

1. Careful Administration (This product should be administered with care in the following patients.)
   (1) Patients with prostatic hyperplasia
      [This product may induce dysuria.]
   (2) Patients with congestive heart failure
      [Symptoms may be exacerbated.]
   (3) Patients with arrhythmia
      [Symptoms may be exacerbated.]
   (4) Patients with ulcerative colitis
      [Toxic megacolon may occur.]
   (5) Patients with hyperthyroidism
      [Symptoms may be exacerbated.]
   (6) Patients in a high-temperature environment
      [Body temperature may increase due to decreased sweating.]

2. Important Precautions

Since administration of this product may induce mydriasis, dizziness and others, patients should be cautioned against engaging in potentially hazardous activities requiring alertness, such as operating machines or driving cars.
3. Drug Interactions

(1) Precautions for coadministration (This product should be administered with care when coadministered with the following drugs.)

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Signs, Symptoms and Treatment</th>
<th>Mechanism and Risk Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tricyclic antidepressants:</td>
<td>Adverse reactions associated with anticholinergic action may occur.</td>
<td>These drugs may enhance the effect of this product.</td>
</tr>
<tr>
<td>Imipramine, etc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenothiazine preparations: Chlorpromazine, etc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monoamine oxidase inhibitors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antihistamines: Diphenhydramine, etc.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4. Adverse Reactions

This product has not been investigated (Drug-use results surveys, etc.) to determine the incidence of adverse reactions.

(1) Significant adverse reactions

Hepatic dysfunction and jaundice (incidence unknown)

Since administration of this product may induce hepatic dysfunction and jaundice with marked increases in AST (GOT) and ALT (GPT), patients should be carefully monitored. If such an abnormality is observed, administration should be discontinued with appropriate measures taken.

(2) Other adverse reactions

<table>
<thead>
<tr>
<th>Ophthalmic</th>
<th>Incidence unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal</td>
<td>Thirst, nausea/vomiting, anorexia, abdominal enlarged feeling, constipation, etc.</td>
</tr>
<tr>
<td>Hepatic</td>
<td>Increases in AST (GOT), ALT (GPT), γ-GTP and total bilirubin</td>
</tr>
<tr>
<td>Urologic</td>
<td>Dysuria</td>
</tr>
<tr>
<td>Psychoneurologic</td>
<td>Dizziness</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Palpitation</td>
</tr>
<tr>
<td>Hypersensitivity*</td>
<td>Rash</td>
</tr>
<tr>
<td>Others</td>
<td>Malaise, weakness</td>
</tr>
</tbody>
</table>

Note) When any of adverse reactions is observed, administration should be discontinued.

5. Use in the Elderly

Since elderly patients often have reduced physiological functions, careful supervision and measures such as a reduction in the dose are recommended.

6. Precautions Concerning Use

Precautions regarding dispensing: For the drug that is dispensed in a press-through package (PTP), patients should be instructed to remove the drug from the PTP sheet prior to use.

[It has been reported that if the PTP sheet is swallowed, its sharp corners may puncture the esophageal mucosa, resulting in serious complications such as mediastinitis.]

PHARMACOLOGY

1. Anticholinergic Effect

Piperidolate hydrochloride inhibits intestinal cramp induced by acetylcholine (rats and dogs).

2. Inhibitory Effects on Contraction of Oddi’s Sphincter, Duodenum and Renal Tubules

Piperidolate hydrochloride has more potent inhibitory effects on contraction of Oddi’s sphincter, duodenum and renal tubules induced by an intravenous injection of neostigmine than papaverine (dogs).

3. Inhibitory Effect on Ileum

Piperidolate hydrochloride at 2.5 x 10^-6 (the final concentration) induces depressions in tension and motor of isolated ileum (rabbits) suspended in Tyrode solution.

4. Local Anesthetic Effect

Piperidolate hydrochloride has local anesthetic action similar to that of cocaine in the conjunctiva of rabbits.

5. Inhibitory Effect on Contraction of Uterine Smooth Muscle

Piperidolate hydrochloride inhibits contraction of the uterine smooth muscle induced by acetylcholine, Valium, or oxytocin during the late phase of pregnancy (rats).

PHYSICOCHEMISTRY

Nonproprietary name: Piperidolate hydrochloride (JAN)

Chemical name: N-Ethyl-3-piperidyl diphenylacetate hydrochloride

Molecular formula: C_{21}H_{25}NO_{2} \cdot HCl

Molecular weight: 359.89

Structural formula:

\[ \text{\begin{picture}(30,30)
\put(0,0){\includegraphics{structure.png}}
\end{picture}} \]

Melting point: 194 to 198 °C

Description:

Piperidolate hydrochloride occurs as a white crystalline powder with no odor. It is freely soluble in acetic acid (100) and chloroform, soluble in ethanol (95), sparingly soluble in water, slightly soluble in acetic anhydride, and practically insoluble in diethyl ether.

Partition coefficient:

Piperidolate hydrochloride was not distributed to the water layer in chloroform-water system at pH values of 7 to 11 at 24 °C.

PACKAGING

DACTIRAN Tablets 50 mg

PTP: 500 tablets (10 tablets x 50)

REFERENCES

2) Chen J.Y.P et al., J. Pharm. Exp. Ther., 104, 269 (1952)

REQUEST FOR LITERATURE SHOULD BE MADE TO:
Kyorin Pharmaceutical Co, Ltd. Drug Information Center
6, Kanda surugadai 4-chome, Chiyoda-ku, Tokyo 101-8311, Japan
TEL: 0120-409-341 (Toll-free)
9:00 to 17:30 (Monday through Friday exclusive of national holidays)

Manufactured and Marketed (Imported) by:
Kyorin Pharmaceutical Co., Ltd.
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo 101-8311, Japan